Related Experiment Videos
MK-0991 (Merck & Co)
1Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20891, USA. grolla@mail.nih.gov
Idrugs : the Investigational Drugs Journal
|August 23, 2005
Summary
Merck
Area of Science:
- Pharmacology
- Mycology
- Clinical Trials
Background:
- Merck is developing MK-0991 (L-743872), an echinocandin-type antifungal agent.
- MK-0991 functions as a beta-1,3-glucan synthesis inhibitor.
Purpose of the Study:
- To evaluate the efficacy of MK-0991 in treating systemic fungal infections.
- To assess the antifungal activity of MK-0991 against various fungal species, including resistant strains.
Main Methods:
- MK-0991 is undergoing phase III clinical trials.
- The compound was administered intravenously once daily in phase II trials.
- In vitro and in vivo studies were conducted to confirm antifungal activity.
Main Results:
- MK-0991 demonstrated antifungal activity against Candida (including azole-resistant strains), Aspergillus, and other fungi.
- In vitro activity has been validated by multiple studies.
- Financial projections indicate significant market potential, with predicted peak annual sales of 1 billion USD.
Conclusions:
- MK-0991 shows promise as a treatment for systemic fungal infections.
- The drug's efficacy against a range of fungi, including resistant strains, supports its therapeutic potential.
- Clinical trials and market analyses suggest a strong future for this antifungal agent.